Financial insights of BIAF

MyFinsight

For the quarter ending 2025-09-30, BIAF made $1,446,066 in revenue. -$5,051,084 in net income. Net profit margin of -349.30%.

Unit: Dollar

Income Statement	2025-09-30	2025-06-30	2024-09-30	2024-06-30
Net revenue	1,446,066	1,269,483	2,350,386	2,397,652
Direct costs and expenses	942,211	1,016,602	1,440,158	1,407,710
Research and development	330,589	311,372	274,497	402,433
Clinical development	143,311	129,279	93,705	51,462
Selling, general and administrative	2,209,441	2,214,561	2,364,592	2,472,775
Depreciation and amortization	113,360	113,229	151,298	151,070
Total operating expenses	3,738,912	3,785,043	4,324,250	4,485,450
Loss from operations	-2,292,846	-2,515,560	-1,973,864	-2,087,798
Other expense	-	-	-	1
Interest income	1,088	2,025	2,228	5,186
Interest expense	5,358	10,460	21,631	22,249
Other income	513	38,053	9,683	-
Other expense	3,839	483,043	14,697	-
Change in fair value of warrants issued	2,747,460	1,062,818	-	-
Total other income (expense), net	-2,755,056	-1,516,243	-24,417	-17,062
Net loss before provision for income tax expense	-5,047,902	-4,031,803	-1,998,281	-2,104,860
Provision for income tax expense	3,182	28,984	2,559	5,419
Net loss	-5,051,084	-4,060,787	-2,000,840	-2,110,279

Net loss per common share, basic	-4.74	-0.17	-0.16	-0.19
Net loss per common share, diluted	-4.74	-0.17	-0.16	-0.19
Weighted average common shares outstanding, basic	1,066,350	24,021,546	12,391,867	11,389,308
Weighted average common shares outstanding, diluted	1,066,350	24,021,546	12,391,867	11,389,308